 <h1>Alendronate Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of alendronate include:</b> decreased serum calcium and decreased serum phosphate. <b>Other side effects include:</b> arthralgia, myalgia, and ostealgia.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to alendronate: oral solution, oral tablet, oral tablet effervescent</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, alendronate may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking alendronate:</p><p>
<i>More common</i>
</p><ul>
<li>Stomach pain</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Difficulty with swallowing</li>
<li>heartburn</li>
<li>irritation or pain of the esophagus</li>
<li>muscle pain</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Skin rash</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Blistering, peeling, or loosening of the skin</li>
<li>bloating or swelling of the face, arms, hands, lower legs, or feet</li>
<li>bone, joint, or muscle pain, severe and occasionally incapacitating</li>
<li>chest pain</li>
<li>chills</li>
<li>confusion</li>
<li>convulsions</li>
<li>cough</li>
<li>diarrhea</li>
<li>difficulty with breathing</li>
<li>difficulty with moving</li>
<li>heartburn</li>
<li>heavy jaw feeling</li>
<li>hives or welts</li>
<li>irregular heartbeats</li>
<li>itching</li>
<li>joint pain</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs</li>
<li>loosening of a tooth</li>
<li>muscle aching or cramping</li>
<li>muscle cramps in the hands, arms, feet, legs, or face</li>
<li>numbness and tingling around the mouth, fingertips, or feet</li>
<li>pain or burning in the throat</li>
<li>pain, swelling, or numbness in the mouth or jaw</li>
<li>rapid weight gain</li>
<li>red skin lesions, often with a purple center</li>
<li>red, irritated eyes</li>
<li>redness of the skin</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots on the lips or tongue or inside the mouth</li>
<li>stomach cramps</li>
<li>swollen joints</li>
<li>tingling of the hands or feet</li>
<li>tremor</li>
<li>trouble breathing</li>
<li>unusual tiredness or weakness</li>
<li>unusual weight gain or loss</li>
<li>vomiting</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of alendronate may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common</i>
</p><ul>
<li>Constipation</li>
<li>diarrhea</li>
<li>full or bloated feeling</li>
<li>gas</li>
<li>headache</li>
<li>nausea</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Blurred vision or other change in vision</li>
<li>dizziness or lightheadedness</li>
<li>eye pain</li>
<li>feeling of constant movement of self or surroundings</li>
<li>general feeling of discomfort or illness</li>
<li>hair loss or thinning of the hair</li>
<li>sensation of spinning</li>
<li>sensitivity of the eye to light</li>
<li>tearing</li>
</ul><p>
<!-- end oral solution, oral tablet, oral tablet effervescent --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to alendronate: oral solution, oral tablet, oral tablet effervescent</i></p><h3>General</h3><p>Generally, this drug has been well tolerated.  Adverse effects usually have been mild when patients adhered to prescribing instructions.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Bone, muscle or joint pain (sometimes severe)</p>
<p><b>Common</b> (1% to 10%): Muscle cramp, joint swelling</p>
<p><b>Rare</b> (less than 0.1%): Osteonecrosis of the jaw, atypical subtrochanteric and diaphyseal femoral fractures</p>
<p><b>Postmarketing reports</b>: Myalgia, low-energy femoral shaft and subtrochanteric fractures<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Alopecia, pruritus</p>
<p><b>Uncommon</b> (0.1% to 1%): Rash, erythema</p>
<p><b>Rare</b> (less than 0.1%): Rash with photosensitivity, severe skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Abdominal pain, dyspepsia, acid regurgitation, nausea, abdominal distension, constipation, diarrhea, flatulence, esophageal ulcer, gastritis, gastroesophageal reflux</p>
<p><b>Uncommon</b> (0.1% to 1%): Gastric ulcer, esophagitis, esophageal erosions, melena, dysphagia, vomiting</p>
<p><b>Rare</b> (less than 0.1%): Esophageal stricture, oropharyngeal ulceration, upper gastrointestinal PUB (perforation, ulcers, bleeding)</p>
<p><b>Postmarketing reports</b>: Localized osteonecrosis of the jaw, generally associated with tooth extraction and/or local infection with delayed healing<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache, dizziness</p>
<p><b>Uncommon</b> (0.1% to 1%): Dysgeusia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Vertigo, asthenia, peripheral edema</p>
<p><b>Uncommon</b> (0.1% to 1%): Transient symptoms of myalgia, malaise and rarely, typically in association with initiation of treatment<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Uncommon</b> (0.1% to 1%): Eye inflammation (uveitis, scleritis, episcleritis)<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Rare</b> (less than 0.1%): Symptomatic hypocalcemia (often in association with predisposing conditions)<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Rare</b> (less than 0.1%): Urticaria, angioedema<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Postmarketing reports</b>: Acute asthma exacerbations<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Bauer DC, Black D, Ensrud K, Thompson D, Hochberg M, Nevitt M, Musliner T, Freedholm D "Upper gastrointestinal tract safety profile of alendronate - The Fracture Intervention Trial." Arch Intern Med 160 (2000): 517-25</p><p id="ref_2">2. "Product Information. Fosamax (alendronate)." Merck &amp; Co, Inc, West Point, PA. </p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_4">4. Lowe CE, Depew WT, Vanner SJ, Paterson WG, Meddings JB "Upper gastrointestinal toxicity of alendronate." Am J Gastroenterol 95 (2000): 634-40</p><p id="ref_5">5. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_6">6. Ringe JD "The interpretation of preclinical data in predicting bisphosphonate response in the treatment of osteoporosis." Clin Ther 20 (1998): 648-60</p><p id="ref_7">7. Liberman UA, Weiss SR, Broll J, et al. "Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis." N Engl J Med 333 (1995): 1437-43</p><p id="ref_8">8. Ravn P, Bidstrup M, Wasnich RD, et al. "Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study: a randomized, controlled trial." Ann Intern Med 131 (1999): 935-42</p><p id="ref_9">9. Chesnut CH 3rd, McClung MR, Ensrud KE, Bell NH, Genant HK, Harris ST, Singer FR, Stock JL, Yood RA, Delmas PD, et al "Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling." Am J Med 99 (1995): 144-52</p><p id="ref_10">10. Castell DO ""Pill esophagitis"--the case of alendronate." N Engl J Med 335 (1996): 1058-9</p><p id="ref_11">11. Cameron RB "Esophagitis dissecans superficialis and alendronate: case report." Gastrointest Endosc 46 (1997): 562-3</p><p id="ref_12">12. Abdelmalek MF, Douglas DD "Alendronate-induced ulcerative esophagitis." Am J Gastroenterol 91 (1996): 1282-3</p><p id="ref_13">13. Nightingale SL "Important information regarding alendronate adverse reactions." JAMA 275 (1996): 1534</p><p id="ref_14">14. Levine J, Nelson D "Esophageal stricture associated with alendronate therapy." Am J Med 102 (1997): 489-91</p><p id="ref_15">15. Miller PD, Woodson G, Licata AA, Ettinger MP, Mako B, Smith ME, Wang LX, Yates J, Melton ME, Palmisano JJ "Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms." Clin Ther 22 (2000): 1433-42</p><p id="ref_16">16. Adami S, Mian M, Gatti P, Rossini M, Zamberlan N, Bertoldo F, Lo Cascio V "Effects of two oral doses of alendronate in the treatment of Paget's disease of bone." Bone 15 (1994): 415-7</p><p id="ref_17">17. Beauchesne MF, Miller PF "Etidronate and alendronate in the treatment of postmenopausal osteoporosis." Ann Pharmacother 33 (1999): 587-99</p><p id="ref_18">18. Colina RE, Smith M, Kikendall JW, Wong RK "A new probable increasing cause of esophageal ulceration: alendronate." Am J Gastroenterol 92 (1997): 704-6</p><p id="ref_19">19. McClung M, Clemmesen B, Daifortis A, et al. "Alendronate prevents postmenopausal bone loss in women without osteoporosis: a double-blind, randomized, controlled trial." Ann Intern Med 128 (1998): 253-61</p><p id="ref_20">20. Rimmer DE, Rawls DE "Improper alendronate administration and a case of pill esophagitis." Am J Gastroenterol 91 (1996): 2648-9</p><p id="ref_21">21. Graham DY, Malaty HM "Alendronate and naproxen are synergistic for development of gastric ulcers." Arch Intern Med 161 (2001): 107-10</p><p id="ref_22">22. Yue QY, Mortimer O "Alendronate - Risk for esophageal stricture." J Am Geriat Soc 46 (1998): 1581-2</p><p id="ref_23">23. Maconi G, Porro GB "Multiple ulcerative esophagitis caused by alendronate." Am J Gastroenterol 90 (1995): 1889-90</p><p id="ref_24">24. Liberman UA, Hirsch LJ "Esophagitis and alendronate." N Engl J Med 335 (1996): 1069-70</p><p id="ref_25">25. Solomon DH,  Patrick A,  Brookhart MA "More on reports of esophageal cancer with oral bisphosphonate use." N Engl J Med 360 (2009): 1789-90; author reply 1791-2</p><p id="ref_26">26. Graham, Malaty "Alendronate and naproxen are synergistic for development of gastric ulcers (Vol 161, pg 107, 1921)." Arch Intern Med 161 (2001): 1862</p><p id="ref_27">27. Famularo G,  De Simone C "Fatal esophageal perforation with alendronate." Am J Gastroenterol 96 (2001): 3212-3</p><p id="ref_28">28. Bone HG, Greenspan SL, McKeever C, Bell N, Davidson M, Downs RW, Emkey R, Meunier PJ, Miller SS, Mulloy AL, Recker RR, We "Alendronate and estrogen effects in postmenopausal women with low bone mineral density." J Clin Endocrinol Metab 85 (2000): 720-6</p><p id="ref_29">29. Wallace JL "Upper gastrointestinal ulceration with alendronate." Digest Dis Sci 44 (1999): 311-2</p><p id="ref_30">30. Devogelaer JP "Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis (vol 18, pg 141, 1996)." Bone 19 (1996): 78</p><p id="ref_31">31. Cummings SR, Black DM, Thompson DE, et al. "Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial." JAMA 280 (1998): 2077-82</p><p id="ref_32">32. Peter CP "Upper gastrointestinal ulceration with alendronate - Response." Digest Dis Sci 44 (1999): 312-3</p><p id="ref_33">33. Watts NB, Becker P "Alendronate increases spine and hip bone mineral density in women with postmenopausal osteoporosis who failed to respond to intermittent cyclical etidronate." Bone 24 (1999): 65-8</p><p id="ref_34">34. Lanza F,  Sahba B,  Schwartz H, et al. "The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study." Am J Gastroenterol 97 (2002): 58-64</p><p id="ref_35">35. Lourwood DL "The pharmacology and therapeutic utility of bisphosphonates." Pharmacotherapy 18 (1998): 779-89</p><p id="ref_36">36. Degroen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, Pryortillotson S, Seleznick MJ, Pinkas H, Wang KK "Esophagitis associated with the use of alendronate." N Engl J Med 335 (1996): 1016-21</p><p id="ref_37">37. Nussbaum SR, Warrell RP Jr, Rude R, Glusman J, Bilezikian JP, Stewart AF, Stepanavage M, Sacco JF, Averbuch SD, Gertz BJ "Dose-response study of alendronate sodium for the treatment of cancer- associated hypercalcemia." J Clin Oncol 11 (1993): 1618-23</p><p id="ref_38">38. Mbekeani JN, Slamovits TL, Schwartz BH, Sauer HL "Ocular inflammation associated with alendronate therapy." Arch Ophthalmol 117 (1999): 837-8</p><p id="ref_39">39. Isik A,  Uras I,  Uyar ME,  Karakurt F,  Kaftan O "Alendronate-induced asthma." Ann Pharmacother 43 (2009): 547-8</p></div>
<div class="more-resources" id="moreResources">
<h2>More about alendronate</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Patient Tips</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Support Group</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>110 Reviews</li>
<li>Drug class: bisphosphonates</li>
<li>FDA Alerts (3)</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Alendronate &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Fosamax, Binosto</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +3 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Osteoporosis</li>
<li>Paget's Disease</li>
<li>Prevention of Osteoporosis</li>
<li>Aseptic Necrosis</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to alendronate: oral solution, oral tablet, oral tablet effervescent</i></p><h3>General</h3><p>Generally, this drug has been well tolerated.  Adverse effects usually have been mild when patients adhered to prescribing instructions.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Bone, muscle or joint pain (sometimes severe)</p><p><b>Common</b> (1% to 10%): Muscle cramp, joint swelling</p><p><b>Rare</b> (less than 0.1%): Osteonecrosis of the jaw, atypical subtrochanteric and diaphyseal femoral fractures</p><p><b>Postmarketing reports</b>: Myalgia, low-energy femoral shaft and subtrochanteric fractures<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Alopecia, pruritus</p><p><b>Uncommon</b> (0.1% to 1%): Rash, erythema</p><p><b>Rare</b> (less than 0.1%): Rash with photosensitivity, severe skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Abdominal pain, dyspepsia, acid regurgitation, nausea, abdominal distension, constipation, diarrhea, flatulence, esophageal ulcer, gastritis, gastroesophageal reflux</p><p><b>Uncommon</b> (0.1% to 1%): Gastric ulcer, esophagitis, esophageal erosions, melena, dysphagia, vomiting</p><p><b>Rare</b> (less than 0.1%): Esophageal stricture, oropharyngeal ulceration, upper gastrointestinal PUB (perforation, ulcers, bleeding)</p><p><b>Postmarketing reports</b>: Localized osteonecrosis of the jaw, generally associated with tooth extraction and/or local infection with delayed healing<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache, dizziness</p><p><b>Uncommon</b> (0.1% to 1%): Dysgeusia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Vertigo, asthenia, peripheral edema</p><p><b>Uncommon</b> (0.1% to 1%): Transient symptoms of myalgia, malaise and rarely, typically in association with initiation of treatment<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Uncommon</b> (0.1% to 1%): Eye inflammation (uveitis, scleritis, episcleritis)<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Rare</b> (less than 0.1%): Symptomatic hypocalcemia (often in association with predisposing conditions)<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Rare</b> (less than 0.1%): Urticaria, angioedema<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Postmarketing reports</b>: Acute asthma exacerbations<sup>[Ref]</sup></p><p id="ref_1">1. Bauer DC, Black D, Ensrud K, Thompson D, Hochberg M, Nevitt M, Musliner T, Freedholm D "Upper gastrointestinal tract safety profile of alendronate - The Fracture Intervention Trial." Arch Intern Med 160 (2000): 517-25</p><p id="ref_2">2. "Product Information. Fosamax (alendronate)." Merck &amp; Co, Inc, West Point, PA. </p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_4">4. Lowe CE, Depew WT, Vanner SJ, Paterson WG, Meddings JB "Upper gastrointestinal toxicity of alendronate." Am J Gastroenterol 95 (2000): 634-40</p><p id="ref_5">5. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_6">6. Ringe JD "The interpretation of preclinical data in predicting bisphosphonate response in the treatment of osteoporosis." Clin Ther 20 (1998): 648-60</p><p id="ref_7">7. Liberman UA, Weiss SR, Broll J, et al. "Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis." N Engl J Med 333 (1995): 1437-43</p><p id="ref_8">8. Ravn P, Bidstrup M, Wasnich RD, et al. "Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study: a randomized, controlled trial." Ann Intern Med 131 (1999): 935-42</p><p id="ref_9">9. Chesnut CH 3rd, McClung MR, Ensrud KE, Bell NH, Genant HK, Harris ST, Singer FR, Stock JL, Yood RA, Delmas PD, et al "Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling." Am J Med 99 (1995): 144-52</p><p id="ref_10">10. Castell DO ""Pill esophagitis"--the case of alendronate." N Engl J Med 335 (1996): 1058-9</p><p id="ref_11">11. Cameron RB "Esophagitis dissecans superficialis and alendronate: case report." Gastrointest Endosc 46 (1997): 562-3</p><p id="ref_12">12. Abdelmalek MF, Douglas DD "Alendronate-induced ulcerative esophagitis." Am J Gastroenterol 91 (1996): 1282-3</p><p id="ref_13">13. Nightingale SL "Important information regarding alendronate adverse reactions." JAMA 275 (1996): 1534</p><p id="ref_14">14. Levine J, Nelson D "Esophageal stricture associated with alendronate therapy." Am J Med 102 (1997): 489-91</p><p id="ref_15">15. Miller PD, Woodson G, Licata AA, Ettinger MP, Mako B, Smith ME, Wang LX, Yates J, Melton ME, Palmisano JJ "Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms." Clin Ther 22 (2000): 1433-42</p><p id="ref_16">16. Adami S, Mian M, Gatti P, Rossini M, Zamberlan N, Bertoldo F, Lo Cascio V "Effects of two oral doses of alendronate in the treatment of Paget's disease of bone." Bone 15 (1994): 415-7</p><p id="ref_17">17. Beauchesne MF, Miller PF "Etidronate and alendronate in the treatment of postmenopausal osteoporosis." Ann Pharmacother 33 (1999): 587-99</p><p id="ref_18">18. Colina RE, Smith M, Kikendall JW, Wong RK "A new probable increasing cause of esophageal ulceration: alendronate." Am J Gastroenterol 92 (1997): 704-6</p><p id="ref_19">19. McClung M, Clemmesen B, Daifortis A, et al. "Alendronate prevents postmenopausal bone loss in women without osteoporosis: a double-blind, randomized, controlled trial." Ann Intern Med 128 (1998): 253-61</p><p id="ref_20">20. Rimmer DE, Rawls DE "Improper alendronate administration and a case of pill esophagitis." Am J Gastroenterol 91 (1996): 2648-9</p><p id="ref_21">21. Graham DY, Malaty HM "Alendronate and naproxen are synergistic for development of gastric ulcers." Arch Intern Med 161 (2001): 107-10</p><p id="ref_22">22. Yue QY, Mortimer O "Alendronate - Risk for esophageal stricture." J Am Geriat Soc 46 (1998): 1581-2</p><p id="ref_23">23. Maconi G, Porro GB "Multiple ulcerative esophagitis caused by alendronate." Am J Gastroenterol 90 (1995): 1889-90</p><p id="ref_24">24. Liberman UA, Hirsch LJ "Esophagitis and alendronate." N Engl J Med 335 (1996): 1069-70</p><p id="ref_25">25. Solomon DH,  Patrick A,  Brookhart MA "More on reports of esophageal cancer with oral bisphosphonate use." N Engl J Med 360 (2009): 1789-90; author reply 1791-2</p><p id="ref_26">26. Graham, Malaty "Alendronate and naproxen are synergistic for development of gastric ulcers (Vol 161, pg 107, 1921)." Arch Intern Med 161 (2001): 1862</p><p id="ref_27">27. Famularo G,  De Simone C "Fatal esophageal perforation with alendronate." Am J Gastroenterol 96 (2001): 3212-3</p><p id="ref_28">28. Bone HG, Greenspan SL, McKeever C, Bell N, Davidson M, Downs RW, Emkey R, Meunier PJ, Miller SS, Mulloy AL, Recker RR, We "Alendronate and estrogen effects in postmenopausal women with low bone mineral density." J Clin Endocrinol Metab 85 (2000): 720-6</p><p id="ref_29">29. Wallace JL "Upper gastrointestinal ulceration with alendronate." Digest Dis Sci 44 (1999): 311-2</p><p id="ref_30">30. Devogelaer JP "Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis (vol 18, pg 141, 1996)." Bone 19 (1996): 78</p><p id="ref_31">31. Cummings SR, Black DM, Thompson DE, et al. "Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial." JAMA 280 (1998): 2077-82</p><p id="ref_32">32. Peter CP "Upper gastrointestinal ulceration with alendronate - Response." Digest Dis Sci 44 (1999): 312-3</p><p id="ref_33">33. Watts NB, Becker P "Alendronate increases spine and hip bone mineral density in women with postmenopausal osteoporosis who failed to respond to intermittent cyclical etidronate." Bone 24 (1999): 65-8</p><p id="ref_34">34. Lanza F,  Sahba B,  Schwartz H, et al. "The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study." Am J Gastroenterol 97 (2002): 58-64</p><p id="ref_35">35. Lourwood DL "The pharmacology and therapeutic utility of bisphosphonates." Pharmacotherapy 18 (1998): 779-89</p><p id="ref_36">36. Degroen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, Pryortillotson S, Seleznick MJ, Pinkas H, Wang KK "Esophagitis associated with the use of alendronate." N Engl J Med 335 (1996): 1016-21</p><p id="ref_37">37. Nussbaum SR, Warrell RP Jr, Rude R, Glusman J, Bilezikian JP, Stewart AF, Stepanavage M, Sacco JF, Averbuch SD, Gertz BJ "Dose-response study of alendronate sodium for the treatment of cancer- associated hypercalcemia." J Clin Oncol 11 (1993): 1618-23</p><p id="ref_38">38. Mbekeani JN, Slamovits TL, Schwartz BH, Sauer HL "Ocular inflammation associated with alendronate therapy." Arch Ophthalmol 117 (1999): 837-8</p><p id="ref_39">39. Isik A,  Uras I,  Uyar ME,  Karakurt F,  Kaftan O "Alendronate-induced asthma." Ann Pharmacother 43 (2009): 547-8</p><h2>More about alendronate</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Patient Tips</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Support Group</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>110 Reviews</li>
<li>Drug class: bisphosphonates</li>
<li>FDA Alerts (3)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Alendronate &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +3 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Osteoporosis</li>
<li>Paget's Disease</li>
<li>Prevention of Osteoporosis</li>
<li>Aseptic Necrosis</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>